12.5.2021 10:59:13 CEST | Digizuite A/S |
Investor Nyheder
Digizuite A/S, der netop er blevet optaget på NASDAQ First North, med en overtegning på 276%, øger sit strategiske fokus på LifeScience markedet og tilføjer endnu en kunde i form af den svenske børsnoterede virksomhed Karo Pharma, der har mere end 100 brands, herunder de kendte mærker Decubal og Bronkyl og leverer til mere end 60 lande.
Karo Pharma har indgået en abonnementsaftale på Digizuites™ anerkendte SaaS Digital Asset Management (DAM) løsning og kommer dermed i godt selskab med andre ledende og globale pharma- og lifeScience kunder, som bl.a. schweiziske Lonza og engelske BMA.
Digizuite har oplevet stigende efterspørgsel fra LifeScience virksomheder og tilføjer nu LifeScience blandt selskabets fokusmarkeder som led i realiseringen af selskabets vækstplan. 3. Juni afholder Digizuite et internationalt webinar, hvor DAM for LifeScience præsenteres for potentielle kunder og partnere. Andrew Warrington, Healthcare Industry Manager EMEA, Microsoft har indgående kendskab til denne branches udfordringer og behov for kontrol med marketingmateriale er gæstetaler.
”Vi har oplevet en øget efterspørgsel efter vores løsning til håndtering af visuel marketing content indenfor LifeScience og vi ser et stort fremadrettet potentiale i dette vækstmarked”, siger Kim Wolters, CEO i Digizuite.
”Det er en branche, hvor der er stor fokus på kontrol, sikkerhed og sporing. Det gælder også for det digitale materiale, der både skal være let tilgængeligt, men samtidig under kontrol med sikkerhed for at det er godkendt inden brug. Vi har allerede en række kunder indenfor denne industri og har derfor valgt at øge vores fokus på pharma- og LifeScience markedet fremover”, siger Kim Wolters, CEO, Digizuite.
Kontakter
John Norden, Certified Adviser, Norden CEF ApS, +45 20 72 02 00, jn@nordencef.dk
Kim Wolters, CEO, +45 20 60 97 37, kw@digizuite.com
Oliver Bottelet, CFO, +45 61 69 66 52, ob@digizuite.com
Søren Skovbølling, Bestyrelsesformand, +45 25 31 07 20, ssk@digizuite.com
Om Digizuite A/S
DigizuiteDigizuite er en SaaS-virksomhed inden for Digital Asset Management software (DAM), der samler alt digitalt indhold i én central platform.
Gennem automatiserede workflows og agile integrationer fjerner Digizuite manuelle arbejdsgange og effektivisere hele content værdikæden.
Kunder vælger Digizuite for at have kontrol over hvem, hvor, og hvordan corporate materialer bliver benyttet. Det sikrer brandkontrol, risikoreduktion og er med til at øge effektiviteten og omsætningen.Digizuite er en global vækstvirksomhed og har realiseret 600% vækst i ARR fra 2017-20, og har i dag mere end 50 medarbejdere fordelt på hovedkontor i Danmark, datterselskab i USA og kontorer i UK, Belgien og Ukraine. Karo PharmaKaro Pharma er et medicinalfirma, der har specialiseret sig i salg og markedsføring af receptpligtige lægemidler og håndkøbsprodukter, der sælges på apoteker og i detailhandlen. Karo Pharma’s produkter er tilgængelige i mere end 60 lande, med Europa og Norden som kerne markeder. Karo Pharma har hovedkontor i Stockholm, Sverige og er listet på Nasdaq Stockholm Mid Cap.
Vedhæftninger
Download selskabsmeddelelse.pdf
12.5.2021 10:59:13 CEST | Digizuite A/S |
Investor News
This spring, Karo Pharma – the international provider of healthcare products and services – becomes the newest life sciences customer of Digizuite, the newly public digital asset management (DAM) solutions company. Digizuite was just listed on NASDAQ First North on Friday, May 7, 2021, and was oversubscribed by 276%. Adding Karo Pharma – the Swedish company that supplies 100 well-known healthcare brands to more than 60 countries – to the Digizuite customer base is particularly exciting for the international Digizuite team, who has this year adopted a heightened focus on the life sciences and pharmaceutical markets.
Karo Pharma entered into a SaaS agreement with Digizuite, so its users will consume the DAM solution on a subscription basis. Karo Pharma is in good company with this agreement; several other Digizuite customers are also highly recognized members of the global life sciences industry – including Lonza Group and the British Medical Association.
For detailed insights on why life sciences companies should leverage digital asset management technology, Digizuite will present an international ‘DAM for Life Sciences’ webinar on Thursday, June 3, 2021 at 3:30 PM CET/9:30 AM EDT. During this webinar, Andrew Warrington, Microsoft’s EMEA Healthcare Industry Manager, will join Digizuite presenters with his in-depth knowledge of this industry’s content marketing challenges and will shed light on relevant solutions.
“We have experienced an increased demand within the life sciences industry, for our solution’s ability to handle visual marketing content,” Digizuite CEO Kim Wolters said.
“It is an industry in which there is a strong focus on control, security, and tracking. This also applies to the digital material, which must be easily accessible but also managed so that content will only be used when it is fully approved. We have a number of customers within this industry, so it was an obvious strategy to increase our focus on the life sciences market.”
Contacts
John Norden, Certified Adviser, Norden CEF ApS, +45 20 72 02 00, jn@nordencef.dk
Kim Wolters, CEO, +45 20 60 97 37, kw@digizuite.com
Oliver Bottelet, CFO, +45 61 69 66 52, ob@digizuite.com
Søren Skovbølling, Bestyrelsesformand, +45 25 31 07 20, ssk@digizuite.com
About Digizuite A/S
Digizuite Digizuite is a SaaS company in Digital Asset Management software (DAM) that brings together all digital content in one central platform.
Through automated workflows and agile integrations, Digizuite removes manual workflows and streamlines the entire content value chain.
Customers choose Digizuite to have control over who, where and how corporate materials are used. It ensures fire control, risk reduction and helps to increase efficiency and revenue.Digizuite is a global growth company and has realized 600% growth in ARR between 2017 and 2020. Today, the company has more than 50 employees between its headquarters in Denmark and its subsidiaries in the United States, United Kingdom, Belgium, and Ukraine. Karo PharmaKaro Pharma is a pharmaceutical company that specializes in the sale and marketing of prescription drugs and over-the-counter products sold in pharmacies and retailers. Karo Pharma’s products are available in more than 60 countries, with Europe and the Nordic region as core markets. Karo Pharma is headquartered in Stockholm, Sweden and is listed on the Nasdaq Stockholm Mid Cap.
Attachments
Download announcement as PDF.pdf
